NASDAQ:HRTXHeron Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Heron Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $15.51 -0.33 (-2.08 %) (As of 08/14/2020 04:00 PM ET) Add Compare Share Today's Range$15.41Now: $15.51▼$15.9150-Day Range$14.26MA: $16.43▼$20.5452-Week Range$9.60Now: $15.51▼$26.81Volume435,109 shsAverage Volume1.32 million shsMarket Capitalization$1.41 billionP/E RatioN/ADividend YieldN/ABeta1.7 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron) extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens. The company is also developing CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy; and HTX-011, an investigational, long-acting, and extended-release formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam for post-operative pain management. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.Read More Beat the Market (BTM) Rank™ 4.4 Analyst's Opinion Consensus RatingHeron Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $32.00, Heron Therapeutics has a potential upside of 106.3% from its current price of $15.51.Amount of Analyst CoverageHeron Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.7 Community Rank Outperform VotesHeron Therapeutics has received 623 “outperform” votes. (Add your “outperform” vote.)Underperform VotesHeron Therapeutics has received 519 “underperform” votes. (Add your “underperform” vote.)Community SentimentHeron Therapeutics has received 54.55% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Heron Therapeutics and other stocks. Vote “Outperform” if you believe HRTX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe HRTX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldHeron Therapeutics does not currently pay a dividend.Dividend GrowthHeron Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Heron Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 12.85% of the stock of Heron Therapeutics is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Heron Therapeutics are expected to grow in the coming year, from ($2.45) to ($1.62) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Heron Therapeutics is -6.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Heron Therapeutics is -6.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHeron Therapeutics has a P/B Ratio of 3.46. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 4.4Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.55 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:HRTX Previous Symbol CUSIPN/A CIK818033 Webwww.herontx.com Phone858-251-4400Debt Debt-to-Equity Ratio0.05 Current Ratio4.24 Quick Ratio3.79Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$145.97 million Price / Sales9.65 Cash FlowN/A Price / Cash FlowN/A Book Value$4.48 per share Price / Book3.46Profitability EPS (Most Recent Fiscal Year)($2.50) Net Income$-204,750,000.00 Net Margins-157.65% Return on Equity-57.52% Return on Assets-43.64%Miscellaneous Employees198 Outstanding Shares90,855,000Market Cap$1.41 billion Next Earnings Date11/10/2020 (Estimated) OptionableOptionable $15.51 -0.33 (-2.08 %) (As of 08/14/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive HRTX News and Ratings via Email Sign-up to receive the latest news and ratings for HRTX and its competitors with MarketBeat's FREE daily newsletter. Heron Therapeutics (NASDAQ:HRTX) Frequently Asked Questions How has Heron Therapeutics' stock price been impacted by Coronavirus? Heron Therapeutics' stock was trading at $13.64 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, HRTX shares have increased by 13.7% and is now trading at $15.51. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Heron Therapeutics? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Heron Therapeutics in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Heron Therapeutics. When is Heron Therapeutics' next earnings date? Heron Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020. View our earnings forecast for Heron Therapeutics. How were Heron Therapeutics' earnings last quarter? Heron Therapeutics Inc (NASDAQ:HRTX) released its quarterly earnings data on Wednesday, August, 5th. The biotechnology company reported ($0.61) EPS for the quarter, topping the consensus estimate of ($0.64) by $0.03. Heron Therapeutics had a negative net margin of 157.65% and a negative return on equity of 57.52%. View Heron Therapeutics' earnings history. What price target have analysts set for HRTX? 9 brokers have issued 1-year price objectives for Heron Therapeutics' shares. Their forecasts range from $19.00 to $44.00. On average, they expect Heron Therapeutics' share price to reach $32.00 in the next twelve months. This suggests a possible upside of 106.3% from the stock's current price. View analysts' price targets for Heron Therapeutics. Has Heron Therapeutics been receiving favorable news coverage? News articles about HRTX stock have trended somewhat negative recently, according to InfoTrie Sentiment. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Heron Therapeutics earned a media sentiment score of -1.5 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 7.0 out of 10, meaning that recent news coverage is likely to have an impact on the company's share price in the next several days. View the latest news about Heron Therapeutics. Who are some of Heron Therapeutics' key competitors? Some companies that are related to Heron Therapeutics include Mirati Therapeutics (MRTX), Myokardia (MYOK), Ultragenyx Pharmaceutical (RARE), United Therapeutics (UTHR), Zai Lab (ZLAB), HUTCHISON CHINA/S (HCM), Schrodinger (SDGR), Allakos (ALLK), Blueprint Medicines (BPMC), Arrowhead Pharmaceuticals (ARWR), Evotec (EVTCY), FibroGen (FGEN), Legend Biotech (LEGN), HYPERA S A/S (HYPMY) and Amicus Therapeutics (FOLD). View all competitors. What other stocks do shareholders of Heron Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Heron Therapeutics investors own include Micron Technology (MU), Gilead Sciences (GILD), Immunomedics (IMMU), Pfizer (PFE), bluebird bio (BLUE), Editas Medicine (EDIT), NVIDIA (NVDA), Amarin (AMRN), Crispr Therapeutics (CRSP) and Cara Therapeutics (CARA). Who are Heron Therapeutics' key executives? Heron Therapeutics' management team includes the following people: Dr. Barry D. Quart, Pres, CEO & Director (Age 62)Mr. Robert E. Hoffman C.P.A., CPA, CFO & Sr. VP of Fin. (Age 53)Ms. Kimberly J. Manhard, Exec. VP of Drug Devel. (Age 59)Mr. David L. Szekeres, Sr. VP of Bus. Devel., Gen. Counsel & Corp. Sec. (Age 45)Mr. Sean T. Ristine, VP of HR (Age 49) What is Heron Therapeutics' stock symbol? Heron Therapeutics trades on the NASDAQ under the ticker symbol "HRTX." Who are Heron Therapeutics' major shareholders? Heron Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (8.84%), FMR LLC (2.11%), FIL Ltd (1.58%), Candriam Luxembourg S.C.A. (1.41%), Goldman Sachs Group Inc. (1.31%) and Highland Capital Management Fund Advisors L.P. (0.79%). Company insiders that own Heron Therapeutics stock include Barry D Quart, John Poyhonen, Kevin C Tang, Kimberly Manhard and Waage Christian. View institutional ownership trends for Heron Therapeutics. Which major investors are selling Heron Therapeutics stock? HRTX stock was sold by a variety of institutional investors in the last quarter, including FIL Ltd, UBS Oconnor LLC, FMR LLC, Goldman Sachs Group Inc., Bank of America Corp DE, Stifel Financial Corp, First Trust Advisors LP, and Highland Capital Management Fund Advisors L.P.. View insider buying and selling activity for Heron Therapeutics. Which major investors are buying Heron Therapeutics stock? HRTX stock was acquired by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Holocene Advisors LP, Man Group plc, ClariVest Asset Management LLC, Alps Advisors Inc., Orbimed Advisors LLC, Congress Park Capital LLC, and Tudor Investment Corp Et Al. Company insiders that have bought Heron Therapeutics stock in the last two years include Barry D Quart, John Poyhonen, Kevin C Tang, and Waage Christian. View insider buying and selling activity for Heron Therapeutics. How do I buy shares of Heron Therapeutics? Shares of HRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Heron Therapeutics' stock price today? One share of HRTX stock can currently be purchased for approximately $15.51. How big of a company is Heron Therapeutics? Heron Therapeutics has a market capitalization of $1.41 billion and generates $145.97 million in revenue each year. The biotechnology company earns $-204,750,000.00 in net income (profit) each year or ($2.50) on an earnings per share basis. Heron Therapeutics employs 198 workers across the globe. What is Heron Therapeutics' official website? The official website for Heron Therapeutics is www.herontx.com. How can I contact Heron Therapeutics? Heron Therapeutics' mailing address is 4242 CAMPUS POINT COURT SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-251-4400 or via email at [email protected] This page was last updated on 8/15/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
